Literature DB >> 9737678

Endogenous opioids modulate allograft rejection time in mice: possible relation with Th1/Th2 cytokines.

P Sacerdote1, V E di San Secondo, G Sirchia, B Manfredi, A E Panerai.   

Abstract

The continuous infusion of the opioid peptide beta-endorphin prolongs skin allograft survival in mice, while the opiate receptor antagonist naloxone, administered together with the opioid at the time of transplantation, abolishes the effect of the opioid. Consistently, naloxone, when given alone at the time of transplantation, but not later, accelerates graft rejection and increases splenocyte IL-2 and interferon-gamma (IFN-gamma) production. Splenocyte beta-endorphin concentrations are lower in transplanted animals. The effects of exogenous beta-endorphin and naloxone suggest that the endogenous opioid peptide beta-endorphin exerts a tonic inhibitory effect over early events of T cell-mediated immune responses in vivo. The effects of beta-endorphin and naloxone are consistent with the previously shown role of the opioid system in the modulation of the Th1/Th2 cytokine pattern.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9737678      PMCID: PMC1905056          DOI: 10.1046/j.1365-2249.1998.00680.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  Intermittent but not continuous inescapable footshock stress affects immune responses and immunocyte beta-endorphin concentrations in the rat.

Authors:  P Sacerdote; B Manfredi; M Bianchi; A E Panerai
Journal:  Brain Behav Immun       Date:  1994-09       Impact factor: 7.217

Review 2.  Cytokines and the Th1/Th2 paradigm in transplantation.

Authors:  P Nickerson; W Steurer; J Steiger; X Zheng; A W Steele; T B Strom
Journal:  Curr Opin Immunol       Date:  1994-10       Impact factor: 7.486

3.  Potentiation of cyclosporine A-induced immunosuppression by a lymphocytic low-molecular weight peptide.

Authors:  V E Rosso di San Secondo; A Aniasi; G Piccolo; P C Montecucchi; G Sirchia
Journal:  Transplant Proc       Date:  1994-12       Impact factor: 1.066

4.  Expression of pro-opiomelanocortin gene and quantification of adrenocorticotropic hormone-like immunoreactivity in human normal peripheral mononuclear cells and lymphoid and myeloid malignancies.

Authors:  R Buzzetti; L McLoughlin; P M Lavender; A J Clark; L H Rees
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

5.  The phosphorylation of the CD3 gamma chain of T lymphocytes is modulated by beta-endorphin.

Authors:  A Kavelaars; B J Eggen; P N De Graan; W H Gispen; C J Heijnen
Journal:  Eur J Immunol       Date:  1990-04       Impact factor: 5.532

6.  Evidence for an opioid inhibitory effect on T cell proliferation.

Authors:  B Manfredi; P Sacerdote; M Bianchi; L Locatelli; J Veljic-Radulovic; A E Panerai
Journal:  J Neuroimmunol       Date:  1993-04       Impact factor: 3.478

7.  Decreased immunoreactive beta-endorphin in mononuclear leucocytes from patients with rheumatic diseases.

Authors:  C J Wiedermann; P Sacerdote; E Mur; U Kinigadner; T Wicker; A E Panerai; H Braunsteiner
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

8.  Beta-endorphin content in HIV-infected HuT78 cell line and in peripheral lymphocytes from HIV-positive subjects.

Authors:  W Barcellini; P Sacerdote; M O Borghi; G P Rizzardi; C Fain; C De Giuli Morghen; B Manfredi; A Lazzarin; P L Meroni; A E Panerai
Journal:  Peptides       Date:  1994       Impact factor: 3.750

9.  Age-related changes of beta-endorphin and cholecystokinin in human and rat mononuclear cells.

Authors:  P Sacerdote; M Breda; W Barcellini; P L Meroni; A E Panerai
Journal:  Peptides       Date:  1991 Nov-Dec       Impact factor: 3.750

10.  Decreased beta-endorphin content in peripheral blood mononuclear leukocytes from patients with Crohn's disease.

Authors:  C J Wiedermann; P Sacerdote; A Propst; T Propst; G Judmaier; H Kathrein; W Vogel; A E Panerai
Journal:  Brain Behav Immun       Date:  1994-09       Impact factor: 7.217

View more
  6 in total

1.  Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the Plasmodium vivax recombinant thrombospondin-related adhesive protein (TRAP) in mice.

Authors:  Saeed Nazeri; Sedigheh Zakeri; Akram A Mehrizi; Navid D Djadid; Georges Snounou; Chiara Andolina; François Nosten
Journal:  Med Microbiol Immunol       Date:  2018-06-09       Impact factor: 3.402

Review 2.  Evaluation of the alum-naloxone adjuvant activity against experimental murine leishmaniasis due to L. major.

Authors:  Arezoo Bozorgomid; Habib Mohammadzadeh Hajipirloo; Khosrow Hazrati Tappeh; Naser Nazari; Seyed Ahmad Karamati; Samira Shirooie
Journal:  J Parasit Dis       Date:  2016-01-13

3.  Immunological evaluation of two novel engineered Plasmodium vivax circumsporozoite proteins formulated with different human-compatible vaccine adjuvants in C57BL/6 mice.

Authors:  Samaneh H Shabani; Sedigheh Zakeri; Yousef Mortazavi; Akram A Mehrizi
Journal:  Med Microbiol Immunol       Date:  2019-04-25       Impact factor: 3.402

Review 4.  Roles of β-Endorphin in Stress, Behavior, Neuroinflammation, and Brain Energy Metabolism.

Authors:  Alexander Pilozzi; Caitlin Carro; Xudong Huang
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

5.  The mechanism of effective electroacupuncture on T cell response in rats with experimental autoimmune encephalomyelitis.

Authors:  Yumei Liu; Hongwei Wang; Xinyue Wang; Lili Mu; Qingfei Kong; Dandan Wang; Jinghua Wang; Yao Zhang; Jinfeng Yang; Mingyan Zhou; Guangyou Wang; Bo Sun; Hulun Li
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240

Review 6.  Opioids and Viral Infections: A Double-Edged Sword.

Authors:  Alireza Tahamtan; Masoumeh Tavakoli-Yaraki; Talat Mokhtari-Azad; Majid Teymoori-Rad; Louis Bont; Fazel Shokri; Vahid Salimi
Journal:  Front Microbiol       Date:  2016-06-22       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.